Myovant Sciences Announces Corporate Updates and Financial Results for Third Fiscal Quarter 2022
26 janv. 2023 16h05 HE
|
Myovant Sciences, Inc.
Third fiscal quarter 2022 total revenue of $100.2 million; including net product revenue of $61.4 millionNet product revenue from U.S. sales of ORGOVYX® of $48.7 million in third fiscal quarter 2022,...
Myovant Sciences Announces New Employment Inducement Grants Under NYSE Rule 303A.08
16 nov. 2022 16h45 HE
|
Myovant Sciences, Inc.
BASEL, Switzerland, Nov. 16, 2022 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV), a biopharmaceutical company that aspires to redefine care for women and for men through purpose-driven science,...
Myovant Sciences Appoints Ann Tomlin as Senior Vice President of Human Resources
16 nov. 2022 06h45 HE
|
Myovant Sciences, Inc.
BASEL, Switzerland, Nov. 16, 2022 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV) today announced the appointment of Ann Tomlin as Senior Vice President of Human Resources. Beginning November 28,...
Myovant Sciences Announces Corporate Updates and Financial Results for Second Fiscal Quarter 2022
26 oct. 2022 08h30 HE
|
Myovant Sciences, Inc.
On October 23, 2022, Sumitovant Biopharma Ltd. (Sumitovant), in conjunction with parent company Sumitomo Pharma Co., Ltd. (Sumitomo Pharma), and Myovant Sciences (Myovant) announced that they have...
Myovant Sciences Cancels Second Quarter Earnings Conference Call
24 oct. 2022 16h30 HE
|
Myovant Sciences, Inc.
BASEL, Switzerland, Oct. 24, 2022 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV) (“Myovant”) today announced the cancellation of its earnings conference call for the quarter ended September 30,...
Myovant Sciences Announces New Employment Inducement Grants Under NYSE Rule 303A.08
18 oct. 2022 16h30 HE
|
Myovant Sciences, Inc.
BASEL, Switzerland, Oct. 18, 2022 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV), a biopharmaceutical company that aspires to redefine care for women and for men through purpose-driven science,...
CORRECTION -- Myovant Sciences, Inc.
14 oct. 2022 10h02 HE
|
Myovant Sciences, Inc.
BASEL, Switzerland, Oct. 14, 2022 (GLOBE NEWSWIRE) -- In a release issued under the headline "Myovant Sciences to Host Second Fiscal Quarter 2022 Earnings Conference Call at 5:00 p.m." earlier today...
Myovant Sciences to Host Second Fiscal Quarter 2022 Earnings Conference Call at 5:00 p.m.
14 oct. 2022 06h45 HE
|
Myovant Sciences, Inc.
BASEL, Switzerland, Oct. 14, 2022 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV), today announced it will host a webcast and conference call to discuss corporate updates and financial results for...
Myovant Sciences Special Committee of Board Confirms Receipt of Preliminary, Non-binding Proposal from Sumitovant Biopharma and Sumitomo Pharma to Acquire Remaining Shares
02 oct. 2022 19h36 HE
|
Myovant Sciences, Inc.
BASEL, Switzerland, Oct. 02, 2022 (GLOBE NEWSWIRE) -- Myovant Sciences Ltd. (NYSE: MYOV) (the “Company”) confirmed today that it has received a preliminary, non-binding proposal (the “Proposal”)...
Myovant Sciences Announces New Employment Inducement Grants Under NYSE Rule 303A.08
16 sept. 2022 16h30 HE
|
Myovant Sciences, Inc.
BASEL, Switzerland, Sept. 16, 2022 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV), a biopharmaceutical company that aspires to redefine care for women and for men through purpose-driven science,...